Microbot Medical (NASDAQ:MBOT) Issues Earnings Results, Beats Estimates By $0.07 EPS

Microbot Medical (NASDAQ:MBOT - Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.07, Zacks reports.

Microbot Medical Trading Up 3.5%

NASDAQ:MBOT traded up $0.09 during trading hours on Monday, reaching $2.66. 1,026,482 shares of the company traded hands, compared to its average volume of 2,271,679. The business's 50-day moving average price is $2.14 and its two-hundred day moving average price is $1.70. Microbot Medical has a 1 year low of $0.82 and a 1 year high of $3.38. The stock has a market capitalization of $96.77 million, a P/E ratio of -3.32 and a beta of 1.15.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Microbot Medical stock. Goldman Sachs Group Inc. purchased a new stake in shares of Microbot Medical Inc. (NASDAQ:MBOT - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 37,744 shares of the biotechnology company's stock, valued at approximately $57,000. Goldman Sachs Group Inc. owned about 0.11% of Microbot Medical as of its most recent SEC filing. Institutional investors and hedge funds own 16.30% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and set a $9.00 target price on shares of Microbot Medical in a research note on Thursday, April 10th.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.